Medios AG

Medios AG

ILM1.DEPre-clinical
Berlin, GermanyFounded 2004medios.ag

Medios AG is a Germany-based specialty pharma company that acts as a crucial intermediary in the pharmaceutical supply chain, ensuring the reliable supply of complex, often high-cost medications to patients with chronic conditions. Its core business model revolves around 'Pharmaceutical Care,' providing patient-specific therapies, including compounded medications and specialty drugs, to clinics, pharmacies, and directly to patients. The company has established itself as a significant player in the German market, leveraging its regulatory expertise and logistics network to address the needs of a fragmented healthcare system. Its strategic direction focuses on expanding its portfolio of partnered specialty drugs and enhancing its service offerings in the growing market for personalized medicine.

Market Cap
$387.3M
Founded
2004
Employees
500-1000
Focus
Biotech

ILM1.DE · Stock Price

USD 13.7014.05 (-50.63%)

Historical price data

AI Company Overview

Medios AG is a Germany-based specialty pharma company that acts as a crucial intermediary in the pharmaceutical supply chain, ensuring the reliable supply of complex, often high-cost medications to patients with chronic conditions. Its core business model revolves around 'Pharmaceutical Care,' providing patient-specific therapies, including compounded medications and specialty drugs, to clinics, pharmacies, and directly to patients. The company has established itself as a significant player in the German market, leveraging its regulatory expertise and logistics network to address the needs of a fragmented healthcare system. Its strategic direction focuses on expanding its portfolio of partnered specialty drugs and enhancing its service offerings in the growing market for personalized medicine.

Technology Platform

Integrated service and logistics platform for Pharmaceutical Care, specializing in the sourcing, production, and distribution of specialty pharmaceuticals and patient-specific compounded medications.

Funding History

1

Total raised: $25M

IPO$25MUndisclosedJun 28, 2018

Opportunities

Growth is driven by the increasing prevalence of chronic diseases requiring complex therapies and the pharmaceutical industry's shift towards high-value specialty drugs.
Medios is positioned to expand its portfolio of distributed drugs and deepen its service offerings in therapy management.

Risk Factors

Key risks include changes in German pharmaceutical pricing and reimbursement regulations, dependence on key manufacturer partners, supply chain disruptions for critical drugs, and intensifying competition from larger wholesale groups.

Competitive Landscape

Main competitors include large pharmaceutical wholesalers (e.g., PHOENIX, GEHE/McKesson) and niche specialty distributors. Medios differentiates through its dedicated focus on the specialty pharma segment and its integrated 'Pharmaceutical Care' service model tailored to the German market.

Publications
20

Company Info

TypeServices
Founded2004
Employees500-1000
LocationBerlin, Germany
StagePre-clinical
RevenueRevenue Generating

Trading

TickerILM1.DE
ExchangeXETRA

Contact

medios.aginfo@medios.ag+49 (0)30 232 566 800

Therapeutic Areas

OncologyAutoimmune DiseasesRare DiseasesChronic Diseases

Partners

Various pharmaceutical manufacturers (partnerships for specialty drug distribution).
SIMILAR COMPANIES
300Microns
300Microns
Pre-clinical · Munich
BetaSense
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Mireca Medicines
Pre-clinical · Munich
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile